NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Maplebear Inc. (NASD: CART) will replace Enovis Corp. (NYSE: ENOV) in the S&P MidCap 400, and Enovis will replace Arch Resources Inc. (NYSE: ARCH) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, January 14. S&P SmallCap 600 constituent CONSOL Energy Inc. (NYSE: CEIX) is acquiring Arch Resources in a deal expected to be completed soon, pending final closing conditions. Following completion of the merger, CONSOL Energy will be renamed Core N ...

Wilmington, DE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will meet with investors at the 43nd Annual J.P. Morgan Healthcare Conference with a presentation scheduled for Monday, January 13th, 2025, at 9:45 a.m. PST (12:45 p.m. EST). A link to the live audio webcast, as well as a copy of the accompanying presentation slides and a replay of this event, will be available on the company’s ...

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE .Today, we put medical device concern Enovis Corporation (NYSE: ENOV ) in the spotlight. The company posted a solid third quarter earlier this month, has strong support in the analy ...

Enovis (ENOV) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Individual investo ...

Shares of Enovis (ENOV) have gained 23.6% over the past four weeks to close the last trading session at $47.86, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $66.50 indicates a potential upside of 39%.The average comprises 10 short-term price targets ranging from a low of $50 to a high of $75, with a standard deviation of $8.58. While the lowest estimate indicates an increase ...

Enovis Corporation (NYSE:ENOV) Q3 2024 Results Conference Call November 6, 2024 8:30 AM ET Company Participants Kyle Rose - Vice President of Investor Relations Matt Trerotola - CEO & Chairman Ben Berry - Senior VP & CFO Conference Call Participants Vic Chopra - Wells Fargo Vijay Kumar - Evercore ISI Robbie Marcus - JPMorgan Xuyang Li - Jefferies Jeff Johnson - Baird Brandon Vazquez - William Blair Caitlin Cronin - Canaccord Danielle Antalffy - UBS Mike Matson - Needham & Company Operator Good day, and wel ...

Enovis (ENOV) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.63 per share. This compares to earnings of $0.56 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 15.87%. A quarter ago, it was expected that this manufacturing and engineering company would post earnings of $0.60 per share when it actually produced earnings of $0.62, delivering a surprise of 3.33%.Over the last four qu ...

enovis Enovis Announces Third Quarter 2024 Results • Continued commercial momentum with third-quarter sales growth of 21% on a reported basis and strong adjusted EBITDA margin expansion • Reconstructive sales grew 57% Y/Y on a reported basis and 9% on a Comparable basis • Reported third-quarter net loss from continuing operations of $0.61 per share, adjusted net income per diluted share of $0.73, up +30% Y/Y WILMINGTON, DE, November 6, 2024 (GLOBE NEWSWIRE)—Enovis™ Corporation (NYSE: ENOV), an innovation-dr ...

Continued commercial momentum with third-quarter sales growth of 21% on a reported basis and strong adjusted EBITDA margin expansionReconstructive sales grew 57% Y/Y on a reported basis and 9% on a Comparable basisReported third-quarter net loss from continuing operations of $0.61 per share, adjusted net income per diluted share of $0.73, up +30% Y/Y Wilmington, DE, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced it ...

JMP Securities initiated coverage on Enovis Corporation ENOV, a medical technology company focusing on orthopedics. The analyst adds that the company sells a broad portfolio of products, many of which were added via selective acquisitions (around 20 over the last 4.5 years). The analyst views M&A as a core competency. The company's product offerings span large joint reconstruction implants, extremity solutions, and various prevention and recovery franchises. These lines enable comprehensive care, addressing ...